Synonym
PNT6555; PNT 6555; PNT-6555
IUPAC/Chemical Name
2,2',2''-(10-(2-((4-(((R)-1-((R)-2-boronopyrrolidin-1-yl)-1-oxopropan-2-yl)carbamoyl)benzyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
InChi Key
PTVMRWQEZPTMFA-RDGATRHJSA-N
InChi Code
InChI=1S/C31H48BN7O11/c1-22(31(48)39-8-2-3-25(39)32(49)50)34-30(47)24-6-4-23(5-7-24)17-33-26(40)18-35-9-11-36(19-27(41)42)13-15-38(21-29(45)46)16-14-37(12-10-35)20-28(43)44/h4-7,22,25,49-50H,2-3,8-21H2,1H3,(H,33,40)(H,34,47)(H,41,42)(H,43,44)(H,45,46)/t22-,25+/m1/s1
SMILES Code
OC(CN1CCN(CC(NCC2=CC=C(C(N[C@@H](C(N3[C@H](B(O)O)CCC3)=O)C)=O)C=C2)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
705.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Poplawski SE, Hallett RM, Dornan MH, Novakowski KE, Pan S, Belanger AP,
Nguyen QD, Wu W, Felten AE, Liu Y, Ahn SH, Hergott VS, Jones B, Lai JH, McCann
JAB, Bachovchin WW. Preclinical Development of PNT6555, a Boronic Acid-Based,
Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and
Treatment of FAP-Positive Tumors. J Nucl Med. 2024 Jan 2;65(1):100-108. doi:
10.2967/jnumed.123.266345. PMID: 38050111.
2: Privé BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW,
van Lith SAM, Mehra N, Nagarajah J, Heskamp S, Westdorp H. Fibroblast activation
protein-targeted radionuclide therapy: background, opportunities, and challenges
of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023
Jun;50(7):1906-1918. doi: 10.1007/s00259-023-06144-0. Epub 2023 Feb 23. PMID:
36813980; PMCID: PMC10199876.
3: Bendre S, Kuo HT, Merkens H, Zhang Z, Wong AAWL, Bénard F, Lin KS. Synthesis
and Preclinical Evaluation of Novel 68Ga-Labeled
(R)-Pyrrolidin-2-yl-boronic Acid-Based PET Tracers for Fibroblast
Activation Protein-Targeted Cancer Imaging. Pharmaceuticals (Basel). 2023 May
28;16(6):798. doi: 10.3390/ph16060798. PMID: 37375746; PMCID: PMC10303363.
